NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis $18.41 +0.25 (+1.38%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$18.25 -0.16 (-0.87%) As of 05/22/2026 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AMPH alerts:Sign Up Key Stats Today's Range$17.93▼$18.4450-Day Range$16.87▼$24.0352-Week Range$16.65▼$31.26Volume485,196 shsAverage Volume737,983 shsMarket Capitalization$811.70 millionP/E Ratio11.09Dividend YieldN/APrice Target$24.50Consensus RatingReduce Company Overview Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions. Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels. The company also markets proprietary respiratory therapies, including over-the-counter inhaled products. Amphastar leverages its in-house drug delivery technologies to support both its own product lines and contract manufacturing services for third-party partners. In addition to marketed products, Amphastar maintains a pipeline of new drug candidates and device enhancements, including next-generation inhalation systems and branded formulations. The company’s research and development efforts are centered on improving patient access to essential medications while advancing delivery platforms that enhance convenience and dosing precision. Amphastar primarily serves the U.S. pharmaceutical market, with select international distribution partnerships. Leadership is anchored by Chief Executive Officer Enno Walther, who oversees strategic growth initiatives and manufacturing operations. The company is governed by a board of directors with experience in pharmaceutical development, regulatory affairs and commercial strategy.AI Generated. May Contain Errors. Read More Amphastar Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreAMPH MarketRank™: Amphastar Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 111th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingReduce Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no strong buy ratings, no buy ratings, 7 hold ratings, and 1 sell rating.Upside PotentialAmphastar Pharmaceuticals has a consensus price target of $24.50, representing about 33.1% upside from its current price of $18.41.Amount of Analyst CoverageAmphastar Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amphastar Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth11.60% Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 11.60% in the coming year, from $2.93 to $3.27 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 11.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 11.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.14.Price to Earnings Growth RatioAmphastar Pharmaceuticals has a PEG Ratio of 2.94. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Amphastar Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.55% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 8.71.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently decreased by 8.13%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.32 News SentimentAmphastar Pharmaceuticals has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for AMPH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders29.60% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amphastar Pharmaceuticals' insider trading history. Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMPH Stock News HeadlinesWhy Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower TodayMay 19, 2026 | finance.yahoo.comThe 5 Most Interesting Analyst Questions From Amphastar Pharmaceuticals’s Q1 Earnings CallMay 17, 2026 | finance.yahoo.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day. | Brownstone Research (Ad)Amphastar Pharmaceuticals (NASDAQ:AMPH) Reaches New 52-Week Low - What's Next?May 17, 2026 | americanbankingnews.comAmphastar Pharmaceuticals' (NASDAQ:AMPH) Conservative Accounting Might Explain Soft EarningsMay 15, 2026 | finance.yahoo.comAmphastar Pharmaceuticals' (AMPH) Equal Weight Rating Reaffirmed at Wells Fargo & CompanyMay 15, 2026 | americanbankingnews.comAmphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comQ1 earnings roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) and the rest of the pharmaceuticals segmentMay 13, 2026 | msn.comSee More Headlines AMPH Stock Analysis - Frequently Asked Questions How have AMPH shares performed this year? Amphastar Pharmaceuticals' stock was trading at $26.78 at the beginning of 2026. Since then, AMPH stock has decreased by 31.3% and is now trading at $18.41. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) issued its quarterly earnings data on Thursday, May, 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by $0.28. The firm had revenue of $171.17 million for the quarter, compared to analysts' expectations of $173.46 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 15.12% and a net margin of 11.00%. Read the conference call transcript. When did Amphastar Pharmaceuticals IPO? Amphastar Pharmaceuticals (AMPH) raised $88 million in an IPO on Wednesday, June 25th 2014. The company issued 8,000,000 shares at $10.00-$12.00 per share. Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' top institutional investors include Dimensional Fund Advisors LP (4.55%), Boston Trust Walden Corp (2.12%), Epoch Investment Partners Inc. (2.04%) and Renaissance Technologies LLC (1.26%). Insiders that own company stock include Mary Z Luo, Howard Lee, Rong Zhou, William J Peters, Yakob Liawatidewi, Floyd F Petersen, Richard K Prins and Michael A Zasloff. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amphastar Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/07/2026Today5/22/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, AMPH's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMPH CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,976Year Founded1996Price Target and Rating Average Price Target for Amphastar Pharmaceuticals$24.50 High Price Target$32.00 Low Price Target$19.00 Potential Upside/Downside+33.1%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$1.66 Trailing P/E Ratio11.09 Forward P/E Ratio6.28 P/E Growth2.94Net Income$98.09 million Net Margins11.00% Pretax Margin14.27% Return on Equity15.12% Return on Assets7.14% Debt Debt-to-Equity Ratio0.79 Current Ratio3.85 Quick Ratio2.82 Sales & Book Value Annual Sales$719.89 million Price / Sales1.13 Cash Flow$4.31 per share Price / Cash Flow4.27 Book Value$17.54 per share Price / Book1.05Miscellaneous Outstanding Shares44,090,000Free Float31,041,000Market Cap$811.70 million OptionableOptionable Beta0.97 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:AMPH) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
